SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is trending as the community debates its potential to break through previous highs and drop a zero amidst high social media activity. While some traders express skepticism regarding its longevity, others are actively encouraging aggressive accumulation and engagement to fuel a rally.

Dumb SEND IT

The $DSIT (Dumb SEND IT) community is aggressively pushing for a breakout, driven by the anticipation of official chart integration and a forthcoming website launch. Holders are actively engaged in community-led pump efforts and air-drop incentives, positioning the token as a resilient, community-driven play against skeptics and early profit-takers.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is currently in the spotlight following the announcement of a preliminary Phase 3 trial design for its lead candidate, CAD-1005, aimed at treating heparin-induced thrombocytopenia. While some community members are optimistic about the company's clinical pipeline and potential regulatory progress, others are expressing significant skepticism due to heavy bot-driven social media activity and concerns over the company's long-term capital needs.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following media reports that GameStop is building a stake in the company as a potential acquisition target, sparking widespread debate among investors over the financial feasibility and strategic logic of a merger. Community discussions are highly polarized, with many skeptical of the deal's mechanics while others are closely tracking institutional data and potential share accumulation patterns.

Urban One, Inc. is a multi-media company, which engages in radio broadcasting that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment consists of all radio broadcast results of operations and low powered television operations. The Reach Media segment consists of the results of operations for the related activities and operations of the company’s syndicated shows. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One and CLEO TV operations. The company was founded by Catherine L. Hughes in 1980 and is headquartered in Silver Spring, MD.

Urban One Inc - Ordinary Shares - Class A

Urban One Inc

Urban One is gaining traction as investors speculate on a potential rally leading up to Juneteenth, a trend that has historically drawn significant attention to the stock. The conversation is currently fueled by discussions around micro-float mechanics, recent acquisition news, and comparisons to previous parabolic moves.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Sanofi-Aventis

Sanofi is currently attracting significant investor attention as market participants speculate on the company's M&A strategy, particularly regarding potential acquisitions in the obesity, MASH, and immunology sectors. Community discourse is heavily focused on Sanofi's recent pipeline developments and the perceived need for the pharmaceutical giant to expand its portfolio to counter long-term patent cliff challenges.

Cantor Equity Partners II, Inc. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded on November 11, 2020 and is headquartered in New York, NY.

Cantor Equity Partners II Inc. - Ordinary Shares - Class A

Cantor Equity Partners II Inc

Cantor Equity Partners II is gaining attention as it nears its business combination with Securitize, a leading tokenization infrastructure provider that counts BlackRock and Morgan Stanley among its backers. Community sentiment is highly bullish, with investors positioning themselves in what they view as a rare pure-play opportunity to gain exposure to the emerging real-world asset tokenization market.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following reports that the company is preparing a potential takeover bid for eBay, fueling community speculation on how a strategic merger could transform the retailer into a larger e-commerce powerhouse. The stock is currently dominated by intense retail participation and heightened options activity as traders debate the viability of a large-scale acquisition, potential dilution, and the broader implications for the company's long-term growth trajectory.

Pinterest, Inc. engages in the operation of a pinboard-style photo-sharing website. It allows users to create and manage theme-based image collections such as events, interests, and hobbies. The company was founded by Benjamin Silbermann, Paul Cahill Sciarra, and Evan Sharp in October 2008 and is headquartered in San Francisco, CA.

Pinterest Inc - Ordinary Shares - Class A

Pinterest Inc

Pinterest is experiencing significant volatility as investors react to a revenue miss and cautious forward guidance, while the community actively debates whether the stock is an oversold value opportunity or a long-term play in need of new leadership. Sentiment remains divided between those betting on a technical bounce supported by the company's strong cash position and those frustrated by management's inability to capitalize on a large, active user base.

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Seres Therapeutics Inc

Seres Therapeutics is experiencing heightened investor attention driven by unusual volume and sustained price momentum, sparking renewed community discussions regarding potential buyout scenarios or strategic partnerships. Shareholders remain focused on whether this activity signals a significant corporate development ahead of upcoming fiscal windows, despite ongoing caution from some market participants wary of historical volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

D.A. Davidson & CO. Takes $1.49 Million Position in Tarsus Pharmaceuticals, Inc. $TARS

D.A. Davidson & CO. purchased a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange...

Amgen (AMGN) Q1 Earnings and Revenues Beat Estimates

Amgen (AMGN) delivered earnings and revenue surprises of +8.87% and +1.71%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Jennison Associates LLC Sells 374,511 Shares of Tarsus Pharmaceuticals, Inc. $TARS

Jennison Associates LLC cut its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 14.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange...

Tarsus Pharmaceuticals is Now Oversold (TARS)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...

Universal Beteiligungs und Servicegesellschaft mbH Increases Holdings in Tarsus Pharmaceuticals, Inc. $TARS

Universal Beteiligungs und Servicegesellschaft mbH grew its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 19.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 109,857 shares of the...

Calamos Advisors LLC Makes New $2.82 Million Investment in Tarsus Pharmaceuticals, Inc. $TARS

Calamos Advisors LLC purchased a new position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to its most recent 13F filing with the...

Tarsus Pharmaceuticals (NASDAQ:TARS) Now Covered by Analysts at Oppenheimer

Oppenheimer began coverage on Tarsus Pharmaceuticals in a report on Friday. They set an "outperform" rating and a $98.00 price target for the company...

Tarsus Pharmaceuticals, Inc. $TARS Position Increased by M&T Bank Corp

M&T Bank Corp increased its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 11,730.0% during the 4th quarter, according to the company in its most recent 13F filing with the...

Tarsus Pharmaceuticals (NASDAQ:TARS) Downgraded to "Hold" Rating by Wall Street Zen

Wall Street Zen cut shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday...

Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Down 5.9% - Here's What Happened

Tarsus Pharmaceuticals (NASDAQ:TARS) Stock Price Down 5.9% - What's Next...

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

TARS
Tarsus Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TARS News

TARSTarsus Pharmaceuticals Inc